China, Immuno-oncology, Results

Innovent, Eli Lilly cite a new success for their PD-1 in lung cancer, with a likely pioneering approval in China looming

Here come the made-in-China checkpoints.

Innovent, one of the most prominent operations in the new wave of Chinese biotechs that have been going global recently, has plucked out data from a single cohort of 20 patients to underscore the promise of their PD-1 drug sintilimab.

Innovent isn’t the only Chinese biotech to work on the country’s first wave of locally developed checkpoints. Hengrui has one, initially allied to Incyte, which moved on to another partner after some troubling rashes appeared in patients. And BeiGene along with Shanghai Junshi are all angling for their first China approvals in H1 of next year.

A check of the database at PharmCube in Shanghai revealed 68 different PD-1/L1 drugs in China's pipeline, part of the tsunami of checkpoints that has been forming in Asia. Endpoints' Amber Tong assembled the full list, which you can see below.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 33,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Scientist, Quality Control
Molecular Templates Austin, TX
Receptionist/Administrative Assistant
Molecular Templates Austin, TX
Principal
Flagship Pioneering Cambridge, MA

Visit Endpoints Careers ->